Ligand partner Eisai receives Japan approval for Fycompa injection

Ligand Pharmaceuticals (LGND) “announced that its partner Eisai Co. (ESAIY) obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug Fycompa, or perampanel, in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol(R), a Ligand technology. Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation. ”